Anatomical Therapeutic Chemical Classification System

The Anatomical Therapeutic Chemical (ATC) Classification System is a globally recognized drug classification system maintained by the World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology, designed to classify the active ingredients of drugs according to the organ or system on which they act, as well as their therapeutic, pharmacological, and chemical properties.

History and Development

The origins of the ATC system trace back to the 1970s when the Norwegian Medicinal Depot developed a classification system to facilitate drug utilization studies. Recognizing the need for a standardized international framework to compare drug consumption data across different countries and regions, the World Health Organization adopted and refined this system. In 1996, the ATC system was officially established as an international standard. Since then, it has been continuously updated and maintained by the WHO Collaborating Centre for Drug Statistics Methodology, located in Oslo, Norway, ensuring that it adapts to the introduction of new pharmaceutical substances and evolving medical practices.

Structure and Coding System

The ATC system divides drugs into different groups based on a hierarchical, five-level structure. This hierarchy results in a unique seven-character alphanumeric code for each specific active substance or combination of substances. The levels are defined as follows:

• First Level (Anatomical Main Group): The first character is a single letter indicating the anatomical main group on which the drug acts. There are 14 main groups in total (e.g., A for Alimentary tract and metabolism, C for Cardiovascular system, N for Nervous system). Certain letters, such as E, F, K, O, and U, are not used.
• Second Level (Therapeutic Subgroup): The second and third characters are two digits that specify the therapeutic subgroup within the main anatomical group (e.g., C08 for Calcium channel blockers).
• Third Level (Therapeutic/Pharmacological Subgroup): The fourth character is a single letter indicating the therapeutic or pharmacological subgroup (e.g., C08C for Selective calcium channel blockers with mainly vascular effects).
• Fourth Level (Chemical/Therapeutic/Pharmacological Subgroup): The fifth character is a single letter representing the chemical, therapeutic, or pharmacological subgroup (e.g., C08CA for Dihydropyridine derivatives).
• Fifth Level (Chemical Substance): The sixth and seventh characters are two digits that identify the specific chemical substance or active ingredient (e.g., C08CA01 for Amlodipine).

Assignment of ATC Codes

The assignment of ATC codes is governed by strict guidelines to ensure consistency. Generally, a drug is assigned only one ATC code based on its primary therapeutic use. However, a single active ingredient may receive multiple ATC codes if it is formulated for distinctly different routes of administration (e.g., oral versus topical) or if it is used for significantly different therapeutic indications. For instance, a corticosteroid used topically for dermatological conditions will have a different ATC code than the same corticosteroid administered systemically for endocrine disorders.

Combination products, which contain two or more active ingredients, are also classified within the ATC system. They are typically assigned codes in specific "combinations" subgroups. If a combination product does not fit into an existing combination subgroup, it may be classified under the ATC code of its primary active ingredient.

Defined Daily Dose (DDD)

The ATC system is intrinsically linked to the concept of the Defined Daily Dose (DDD). The DDD is defined by the WHO as the assumed average maintenance dose per day for a drug used for its main indication in adults. By combining the ATC classification with the DDD, researchers and policymakers can measure and compare drug consumption in a standardized unit (DDDs per 1,000 inhabitants per day), independent of package sizes, pricing, or varying national dosage recommendations. This synergy is fundamental to conducting robust drug utilization research.

Applications in Research and Policy

The primary application of the ATC system is in Drug Utilization Research (DUR). By providing a standardized language for drug classification, the ATC system enables the comparison of drug consumption patterns across different populations, healthcare systems, and time periods. Epidemiologists and public health officials use ATC data to monitor prescribing trends, evaluate the impact of health policies, and assess the safety and efficacy of drugs in real-world settings.

Furthermore, the ATC system is widely utilized in health economics and pharmacovigilance. National health insurance schemes and reimbursement agencies often use ATC codes to manage drug formularies, negotiate pricing, and track pharmaceutical expenditures. In pharmacovigilance, regulatory bodies use the system to categorize and analyze adverse drug reaction reports, helping to identify potential safety signals associated with specific drug classes.

Limitations and Considerations

While the ATC system is a powerful tool for statistical and epidemiological research, it has inherent limitations. It is not designed to serve as a recommendation for drug prescribing, nor is it a strict pharmacological or therapeutic classification system. Because the classification is primarily based on the therapeutic intent of a drug, substances with identical pharmacological mechanisms may be placed in different ATC groups if their clinical applications differ. Additionally, the system does not account for pediatric dosing, as the DDD is based on adult maintenance doses. Users must also be aware that the ATC system is updated annually, meaning historical data must be carefully cross-referenced with the specific version of the ATC index used at the time of data collection.

Veterinary Extension (ATCvet)

To accommodate the classification of veterinary medicines, the WHO developed the ATCvet system. The ATCvet codes are largely based on the human ATC system and are typically created by placing the letter "Q" in front of the corresponding human ATC code (e.g., QC08CA01 for veterinary amlodipine). However, the ATCvet system also includes specific codes that are exclusively used for veterinary drugs, such as immunologicals for veterinary use (QI) and antiparasitic products, insecticides, and repellents for veterinary use (QP). This extension ensures that drug utilization research can be effectively applied to animal health and veterinary pharmacology.